Toshio Oyama
Overview
Explore the profile of Toshio Oyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
831
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kimura A, Nakagomi H, Inoue M, Oka T, Hirotsu Y, Amemiya K, et al.
Int Cancer Conf J
. 2024 Jul;
13(3):193-198.
PMID: 38962040
A 61-year-old woman with pathogenic variant had been treated for 20 years and showed dynamic changes in the genomic profile of her metachronous bilateral breast cancer and metastases. She underwent...
2.
Miyashita Y, Hirotsu Y, Nagakubo Y, Kobayashi H, Kawaguchi M, Hata K, et al.
JTO Clin Res Rep
. 2024 Jun;
5(6):100679.
PMID: 38841537
Introduction: NSCLC is a leading cause of cancer-related mortality worldwide. Specific genetic alterations, such as exon 14 (ex14) skipping, have been identified in NSCLC, allowing targeted therapy. Tepotinib, a highly...
3.
Ohyama H, Hirotsu Y, Amemiya K, Amano H, Hirose S, Oyama T, et al.
Diagn Cytopathol
. 2024 Mar;
52(6):325-331.
PMID: 38516904
Objectives: Pancreatic cancer (PC) has a poor prognosis and limited treatment options. Liquid biopsy, which analyzes circulating tumor DNA (ctDNA) in blood, holds promise for precision medicine; however, low ctDNA...
4.
Sakamoto I, Kagami K, Nozaki T, Hirotsu Y, Amemiya K, Oyama T, et al.
Am J Surg Pathol
. 2024 Jan;
48(3):374-375.
PMID: 38238975
No abstract available.
5.
Ohyama H, Hirotsu Y, Amemiya K, Mikata R, Amano H, Hirose S, et al.
Cancer Genet
. 2023 Dec;
280-281:6-12.
PMID: 38113555
Background: Obtaining sufficient tumor tissue for genomic profiling is challenging in pancreaticobiliary cancer (PBCA). We determined the utility of molecular barcoding (MB) of liquid biopsies (bile, duodenal fluid, and plasma)...
6.
Amemiya K, Hirotsu Y, Nagakubo Y, Mochizuki H, Oyama T, Omata M
Pathol Int
. 2023 Nov;
73(12):593-600.
PMID: 37933792
Analyzing RNA samples from formalin-fixed paraffin-embedded (FFPE) tissues is essential for precision medicine. We investigated RNA quantity and quality from FFPE tumor tissues fixed in formalin for various times and...
7.
Sakamoto I, Kagami K, Nozaki T, Hirotsu Y, Amemiya K, Oyama T, et al.
Am J Surg Pathol
. 2023 Aug;
47(10):1144-1150.
PMID: 37528644
Whether immunohistochemistry (IHC) of p53 accurately reflects the TP53 mutational status of endometrial carcinoma (EC) has not yet been established. This study aimed to clarify the relationship between p53 IHC...
8.
Nagakubo Y, Hirotsu Y, Amemiya K, Mochizuki H, Tsutsui T, Kakizaki Y, et al.
Mol Diagn Ther
. 2023 May;
27(4):513-523.
PMID: 37198423
Background And Objective: The Oncomine Dx Target Test (ODxTT) has been used as a companion diagnostic test for lung cancer. Here, we evaluated whether the amount of nucleic acid and...
9.
Ohyama H, Hirotsu Y, Amemiya K, Miura Y, Hirose S, Oyama T, et al.
Cancer
. 2023 Mar;
129(11):1714-1722.
PMID: 36932987
Background: Obtaining sufficient pancreaticobiliary tumor tissue for genomic profiling has limitations. Liquid biopsies using plasma do not provide sufficient sensitivity. Thus, this study aimed to determine the effectiveness of liquid...
10.
Okimoto K, Hirotsu Y, Arai M, Amemiya K, Akizue N, Ohta Y, et al.
Cancer Med
. 2023 Feb;
12(7):8490-8498.
PMID: 36734304
Background: This study aimed to investigate the validity of pathological diagnosis of early CRC (E-CRC) from the genetic background by comparing data of E-CRC to colorectal adenoma (CRA) and The...